There are 16 approved human immunodeficiency virus type 1 (HIV-1) drugs belonging to
three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse …

Medical advances have led to increased numbers of immunocompromised patients living
longer. Coinciding with this increase in the immunocompromised patient population is an …

Several recent reports indicate that the long, clinically latent phase that characterizes human
immunodeficiency virus (HIV) infection of humans is not a period of viral inactivity, but an …

A recombinant virus assay was used to characterize in detail neutralizing antibody
responses directed at circulating autologous HIV in plasma. Examining serial plasma …

A randomized study of antiretroviral management based on pla... : AIDS A randomized study of
antiretroviral management based on plasma genotypic antiretroviral resistance testing in …

The effect of the appearance of drug-resistant human immunodeficiency virus type 1 (HIV-1)
on viral RNA load was studied in patients treated with the reverse transcriptase inhibitor …

A set of mutations [Ala-62--> Val (A62V), V75I, F77L, F116Y, and Q151M] in the polymerase
domain of reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) …

Objective: To evaluate the efficacy and safety of high-dose therapy with the human
immunodeficiency virus (HIV) protease inhibitor saquinavir and to establish the duration of …

Since the discovery of human immunodeficiency virus (HIV) in 1983, significant progress
has been made toward the discovery, development, and licensing of anti-HIV drugs. In vitro …

Objective: To evaluate the association between resistance of human immunodeficiency virus
type 1 (HIV-1) to zidovudine and clinical progression. Design: Retrospective analysis of …